CD4 and familial pancreatic carcinoma: The CXCR4 antagonist BL-8040 has shown promise pre-clinically for its ability to mobilise immune cells in PDAC, specifically CD4+, activated CD8+ T cells and dendritic cells and is now in clinical trials in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial or combination with the anti-PD-L1 mAb Atezolizumab (NCI-2017-01495).